February 2026 - Page 7 of 16

Nvidia and Meta Deepen AI Alliance With Millions of Next-Gen Chips

Posted on February 18, 2026February 18, 2026 by slightbourne@noblecapitalmarkets.com

AI infrastructure is getting another massive upgrade. Nvidia and Meta have announced an expanded multiyear, multigenerational partnership that will deliver millions of Nvidia’s latest GPUs, CPUs, and networking products into Meta’s data centers. The move underscores just how aggressively the world’s largest tech platforms are investing in artificial intelligence — even as investors question the sustainability of that spending.

Under the agreement, Meta will deploy Nvidia’s Blackwell and next-generation Rubin GPUs to train and run AI models across its family of apps, including Facebook, Instagram, and WhatsApp. The chips will power everything from recommendation systems to advanced generative AI tools designed for billions of users worldwide.

Nvidia CEO Jensen Huang described the partnership as a deep integration across computing layers, from GPUs and CPUs to networking and software. The goal is to bring Nvidia’s full-stack AI platform into Meta’s infrastructure, allowing the company’s researchers and engineers to push the boundaries of large-scale AI deployment.

Importantly, Meta will use the chips both in its own data centers and through Nvidia’s Cloud Partner ecosystem, which includes providers like CoreWeave. That hybrid strategy gives Meta additional flexibility to scale workloads quickly without waiting for new facilities to come online.

Beyond GPUs, Meta is also rolling out Nvidia’s Grace CPU-only servers, with plans to adopt the next-generation Vera CPU systems in 2027. These CPU deployments are notable because they signal Nvidia’s growing ambition to compete more directly in the traditional server market long dominated by Intel and AMD. If Nvidia can establish a foothold in CPU-heavy environments alongside its GPU dominance, it could reshape the balance of power in enterprise data centers.

Meta also plans to integrate Nvidia’s Confidential Computing technology into WhatsApp, enhancing privacy protections by enabling secure data processing on GPUs. As AI systems increasingly rely on sensitive personal data, secure processing capabilities are becoming a competitive differentiator.

The announcement comes at a time when AI-related stocks have faced renewed scrutiny. Shares of Nvidia and Meta have cooled in early 2026 amid concerns that hyperscalers may be overspending on AI hardware. Companies such as Microsoft, Amazon, and Google have introduced their own custom AI chips, raising questions about whether Nvidia’s GPUs will remain indispensable.

There are also broader concerns about whether all AI workloads truly require high-performance GPUs, or whether specialized processors could handle certain tasks more efficiently. Yet analysts argue that Nvidia’s advantage lies in versatility. GPUs can support a wide range of AI applications, from training large language models to running inference at scale, while custom chips tend to be optimized for narrower use cases.

For Meta, the decision is clear: scale matters. Running AI at the level required to serve billions of users demands proven hardware, deep software integration, and reliable supply chains. By doubling down on Nvidia, Meta is signaling that it views AI not as an experimental feature, but as core infrastructure for its future.

The partnership reinforces Nvidia’s central role in the AI ecosystem — and shows that, despite market jitters, the largest tech companies are still betting big on next-generation computing power.

Release – EuroDry Ltd. Sets Date for the Release of Fourth Quarter 2025 Results, Conference Call and Webcast

Posted on February 18, 2026February 18, 2026 by aweinsoff@channelchek.com

Research News and Market Data on EDRY

February 18, 2026 09:40 ET | Source: EuroDry Ltd.

ATHENS, Greece, Feb. 18, 2026 (GLOBE NEWSWIRE) — EuroDry Ltd. (NASDAQ: EDRY, the “Company” or “EuroDry”), an owner and operator of drybulk vessels and provider of seaborne transportation for drybulk cargoes, announced today that it will release its financial results for the fourth quarter ended December 31, 2025, on Thursday, February 19, 2026 after market closes in New York.

On the next day, Friday, February 20, 2026, at 8:00 a.m. Eastern Time, the Company’s management will host a conference call and webcast to discuss the results.

Conference Call details:
Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 877 405 1226 (US Toll-Free Dial In) or +1 201 689 7823 (US and Standard International Dial In). Please quote “EuroDry” to the operator and/or conference ID 13758897. Click here for additional participant International Toll-Free access numbers.

Alternatively, participants can register for the call using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option.

Audio Webcast- Slides Presentation:
There will be a live and then archived webcast of the conference call and accompanying slides, available on the Company’s website. To listen to the archived audio file, visit our website http://www.eurodry.gr and click on Company Presentations under our Investor Relations page. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.

The slide presentation for the fourth quarter ended December 31, 2025, will also be available in PDF format 10 minutes prior to the conference call and webcast, accessible on the company’s website (www.eurodry.gr) on the webcast page. Participants to the webcast can download the PDF presentation.

About EuroDry Ltd.
EuroDry Ltd. was formed on January 8, 2018, under the laws of the Republic of the Marshall Islands to consolidate the drybulk fleet of Euroseas Ltd. into a separate listed public company. EuroDry was spunoff from Euroseas Ltd on May 30, 2018; it trades on the NASDAQ Capital Market under the ticker EDRY.

EuroDry operates in the dry cargo, drybulk shipping market. EuroDry’s operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company and Eurobulk (Far East) Ltd. Inc., which are responsible for the day-to-day commercial and technical management and operations of the vessels. EuroDry employs its vessels on spot and period charters and under pool agreements.

The Company has a fleet of 11 vessels, including 3 Panamax drybulk carriers, 5 Ultramax drybulk carriers, 2 Kamsarmax drybulk carriers and 1 Supramax drybulk carrier. EuroDry’s 11 drybulk carriers have a total cargo capacity of 766,420 dwt. After the delivery of two Ultramax vessels in 2027, the Company’s fleet will consist of 13 vessels with a total carrying capacity of 893,420 dwt.

Visit our website www.eurodry.gr

Company Contact
Tasos Aslidis
Chief Financial Officer
EuroDry Ltd.
11 Canterbury Lane,
Watchung, NJ07069
Tel. (908) 301-9091
E-mail: aha@eurodry.gr

Investor Relations /Financial Media
Nicolas Bornozis
Markella Kara
Capital Link, Inc.
230 Park Avenue, Suite 1540
New York, NY 10169
Tel. (212) 661-7566
E-mail: eurodry@capitallink.com

Release – SEGG Media Nominates Daniel Bailey to Board of Directors Following Majority Acquisition of Veloce Media Group

Posted on February 18, 2026February 18, 2026 by aweinsoff@channelchek.com

Research News and Market Data on SEGG

February 18, 2026

PDF Version

Veloce Co-Founder and CEO To Join SEGG Board as Company Accelerates Revenue Growth Sports & Digital Media Platform

FORT WORTH, Texas, Feb. 18, 2026 (GLOBE NEWSWIRE) — Sports Entertainment Gaming Global Corporation (NASDAQ: SEGG, LTRYW) (“SEGG Media” or the “Company”) today announced the nomination of Daniel Bailey, Co-Founder and Chief Executive Officer of Veloce Media Group, to the SEGG Media Board of Directors, in connection with the Company’s acquisition of Veloce.

Bailey’s appointment strengthens SEGG Media’s commercial focus, corporate governance and strategic oversight as the Company accelerates its plans to grow revenue in the global sports and digital media sector.

Strategic Board Appointment

Under Bailey’s leadership, Veloce became one of the fastest-growing platforms operating at the intersection of esports, motorsport, digital content, and gaming. Under his leadership, Veloce has built a diversified commercial ecosystem spanning championship-winning teams, athlete-led content brands, and long-term partnerships with global enterprises including McLaren, Visa, Microsoft, Hilton, LEGO, and others. Bailey was also instrumental in structuring Veloce’s recent acquisition of the rapidly growing content and lifestyle motorsport business Quadrant – co-founded by 2025 Formula One World Champion Lando Norris.

As a SEGG Board member, Bailey expects to contribute direct operating expertise in digital audience monetization, brand partnerships, international expansion, and scalable media execution, which are areas central to SEGG’s 2026 growth strategy.

Robert Stubblefield, CFO and Interim CEO and President of SEGG Media, said: “Dan’s appointment reflects our commitment to aligning operating leadership with governance. Veloce delivers scale, rapidly growing revenues and profits, and high-quality commercial partnerships. Bringing Dan onto the Board ensures strategic continuity and strengthens our ability to execute on integration and growth.”

Bailey commented: “This marks an important milestone for both Veloce and SEGG Media. Combining SEGG Media’s access to public markets and strong domain names with Veloce’s proven revenue model and global partnerships creates a powerful platform for accelerated expansion. I look forward to contributing at Board level as we scale the combined business.”

Acquisition Recap: Majority Interest in Veloce Media Group

As reported yesterday, SEGG Media acquired a majority interest in Veloce Media Group at an enterprise value of approximately $61 million (£45 million).

The transaction was structured as a combination of cash and SEGG Media stock at $10 per share.

Veloce reported approximately $17.5 million (£12.8 million) in revenue for its most recently reported fiscal year and currently generates over 500 million monthly digital views across its ecosystem.

Veloce’s acquisition provides SEGG Media with:

Immediate revenue scale and diversification
Established blue-chip commercial relationships
A high-engagement global digital audience
Expansion across esports, motorsport, gaming, and athlete-led media
Embedded leadership continuity through Board and management integration

The acquisition of Veloce lays the cornerstone for SEGG Media’s Sports business unit and materially enhances the Company’s ability to consolidate operating results, expand internationally, and accelerate top-line growth.

About SEGG Media Corporation
SEGG Media (Nasdaq: SEGG, LTRYW) is a global sports, entertainment and gaming group operating a portfolio of digital assets including Sports.com, Concerts.com and Lottery.com. Focused on immersive fan engagement, ethical gaming and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love.

Important Notice Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “initiatives,” “continue,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, any future findings from ongoing review of the Company’s internal accounting controls, additional examination of the preliminary conclusions of such review, the Company’s ability to secure additional capital resources, the Company’s ability to continue as a going concern, the Company’s ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company’s ability to regain compliance with the Bid Price Requirement, the Company’s ability to regain compliance with Nasdaq Listing Rules, the Company’s ability to become current with its SEC reports, and those additional risks and uncertainties discussed under the heading “Risk Factors” in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.

For additional information, visit www.seggmediacorp.com or contact media relations at media@seggmediacorp.com.

Release – Power Metallic Intercepts 20.40 Meters of 4.11% CuEqRec in Hole 25-046, and 8.60 Meters of 6.84% CuEqRec in Hole 25-045 at Lion

Posted on February 18, 2026February 18, 2026 by aweinsoff@channelchek.com

Research New and Market Data on PNPNF

Feb 18, 2026, 09:18 ET

TORONTO, Feb. 18, 2026 /CNW/ – Power Metallic Mines Inc. (the “Company” or “Power Metallic”) (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV1) is pleased to provide a release of assays from its fall drill program

Summer-Fall Drilling Release 4 – Lion

Figure 1 – Lion Drill holes reported in this news release, with off-hole BHEM anomalies from recent drilling (see Lion- Tiger Deep discussion below) (CNW Group/Power Metallic Mines Inc.)

Figure 2 – Exploration target areas currently being explored on the Nisk Project. (CNW Group/Power Metallic Mines Inc.)

The summer-fall 2025 drilling program was designed to search for extensions to the Lion Zone, specifically down plunge from known mineralization, and to infill drilling the Lion deposit to define the zone geometry to a confidence level that would allow a future mineral resource estimate to be carried out to an Indicated Resource classification.

As assay results are returned from this exploration drilling, they have continued to successfully define the Lion mineralization. The holes in this release are extensions down-plunge from high-grade shoots that are internal to the Lion zone for future MRE modelling. Drilling reported here intersected mineralization below the central high-grade zone of Lion, including a high-grade palladium-platinum-gold-copper intersection of 8.40m @ 8.05% CuEqRec¹included within 20.40m @ 4.11% CuEqRec¹in hole PML-25-046; and 5.10m @ 9.86% CuEqRec¹included in 8.60m of 6.34% CuEqRec¹in hole PML-25-045.

Highlighting the polymetallic nature of Lion the reported results from hole PML-25-046 was expected to be a relatively low-grade hole based on initial observations based on the amount of copper mineralization in the core (veins, stringers, and disseminations). Subsequently the assay results indicated that the 20.4m of moderate copper mineralization (0.88% Cu) carried high values of Pd (5.01 g/t) as well as Pt and Au. Power Metallic is now developing logging procedures to help identify these higher-grade precious metal zones that form part of this orthomagmetic polymetallic deposit.

Extensional intersections on the west side of Lion included 7.66m @ 2.69% CuEqRec¹in hole PML-25-34a, again with significant metal value carried by Pd-Pt. These holes have largely confirmed the grade of the Lion zone as well as increasing the size of the interpreted higher-grade lodes.

Hole PML-25-036 is approximately 150m west of the main Lion zone. This intersection is indicative of another lens of polymetallic mineralization west of Lion and will be followed up by future drilling to expand this zone.

Table 1 – Lion Zone Intersections reported in this News Release

¹Copper Equivalent Rec Calculation (CuEqRec¹)
CuEqRec in represents CuEq calculated based on the following metal prices (USD) : 2,360.15 $/oz Au, 27.98 $/oz Ag, 1,215.00 $/oz Pd, 1000.00 $/oz Pt, 4.00 $/lb Cu, 10.00 $/lb Ni and 22.50 $/lb Co., and recovered grades based on recent locked-cycle metallurgical recoveries by SGS Canada Inc (see press release Jan 21, 2026).

“We have made a lot of progress on the Lion Zone. The continuity and growth of the higher-grade core of Lion zone with in-fill drill holes (MRE holes), coupled with our amazing metal recovery numbers that we reported a couple of weeks ago puts us in great shape to ramp up exploration this year. Commented Power Metallic Ceo Terry Lynch

Exploration Update

Power Metallic is expecting to receive the balance of the fall drill holes within the month of February. It will provide a detailed update on the exploration the company is conducting on Lion West, The Hydro lands, Tiger Deep and the Elephant exploration plays as well as initial exploration on the Li-FT acquisition ground. In addition, there will be further updates on the Lion Zone East expansion drilling following the recently recognized high grade east plunging mineralization structures extending from the Lion main zone.

Qualified Person

Joseph Campbell, P. Geo, VP Exploration at Power Metallic, is the qualified person who has reviewed and approved the technical disclosure contained in this news release.

About Power Metallic Mines Inc.

Power Metallic is a Canadian exploration company focused on advancing the Nisk Project Area (Nisk–Lion–Tiger)–a high–grade Copper–PGE, Nickel, gold and silver system–toward Canada’s next polymetallic mine.

On 1 February 2021, Power Metallic (then Chilean Metals) secured an option to earn up to 80% of the Nisk project from Critical Elements Lithium Corp. (TSX–V: CRE). Following the June 2025 purchase of 313 adjoining claims (~167 km²) from Li–FT Power, the Company now controls ~212.86 km² and roughly 50 km of prospective basin margins.

Power Metallic is expanding mineralization at the Nisk and Lion discovery zones, evaluating the Tiger target, and exploring the enlarged land package through successive drill programs.

Beyond the Nisk Project Area, Power Metallic indirectly has an interest in significant land packages in British Columbia and Chile, by its 50% share ownership position in Chilean Metals Inc., which were spun out from Power Metallic via a plan of arrangement on February 3, 2025.

It also owns 100% of Power Metallic Arabia which owns 100% interest in the Jabul Baudan exploration license in The Kingdon of Saudi Arabia’s JabalSaid Belt. The property encompasses over 200 square kilometres in an area recognized for its high prospectivity for copper gold and zinc mineralization. The region is known for its massive volcanic sulfide (VMS) deposits, including the world-class Jabal Sayid mine and the promising Umm and Damad deposit.

For further information, readers are encouraged to contact:
Power Metallic Mines Inc.
The Canadian Venture Building
82 Richmond St East, Suite 202
Toronto, ON

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

QAQC and Sampling

GeoVector Management Inc (“GeoVector”) is the Consulting company retained to perform the actual drilling program, which includes core logging and sampling of the drill core.

All samples were submitted to and analyzed at Activation Laboratories Ltd (“Actlabs”), an independent commercial laboratory for both the sample preparation and assaying. Actlabs is a commercial laboratory independent of Power Metallic with no interest in the Project. Actlabs is an ISO 9001 and 17025 certified and accredited laboratories. Samples submitted through Actlabs are run through standard preparation methods and analysed using RX-1 (Dry, crush (< 7 kg) up to 80% passing 2 mm, riffle split (250 g) and pulverize (mild steel) to 95% passing 105 μm) preparation methods, and using 1F2 (ICP-OES) and 1C-OES – 4-Acid near total digestion + Gold-Platinum-Palladium analysis and 8-Peroxide ICP-OES, for regular and over detection limit analysis. Pegmatite samples are analyzed using UT7 – Li up to 5%, Rb up to 2% method. Actlabs also undertake their own internal coarse and pulp duplicate analysis to ensure proper sample preparation and equipment calibr

Release – NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

Posted on February 18, 2026February 18, 2026 by aweinsoff@channelchek.com

Research News and Market Data on NRSN

CAMBRIDGE, Mass., Feb. 18, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced the availability of additional long-term survival data from its previously completed PARADIGM Phase 2b clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).

The updated analysis, based on extended follow-up, demonstrates a clinically meaningful and statistically significant improvement in overall survival for patients treated with PrimeC, compared to those initially assigned to placebo.

According to Kaplan–Meier survival estimates, patients who received PrimeC continuously during both the double-blind and open-label phases achieved an estimated median survival of 36.3 months, compared to 21.4 months for patients initially assigned to placebo during the double-blind phase and crossing over to active treatment during the open label extension. This represents over 14-month improvement and approximately a 70% increase in median survival. The survival benefit was sustained over time, with consistent separation between treatment arms throughout the follow-up period.

A log-rank test comparing survival curves demonstrated statistical significance (p = 0.0218).

Further analysis using a Cox proportional hazards model showed that PrimeC treatment was associated with a 65% reduction in the risk of death compared to placebo (hazard ratio: 0.35; 95% CI: 0.17–0.71; p = 0.0037), after adjusting for baseline risk factors.

“The long-term survival data further validate the magnitude and durability of PrimeC’s effect in ALS and reinforce its potential as a disease-modifying therapy,” said Alon Ben-Noon, CEO of NeuroSense. “A 65% reduction in the risk of death and a statistically significant extension in median survival of over 14 months represent a clinically meaningful benefit of notable magnitude in ALS. We believe these findings substantially strengthen the clinical and regulatory foundation as we advance toward late-stage development.”

The PARADIGM Phase 2b trial was a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of PrimeC in 68 people living with ALS. Participants were administered PrimeC or placebo at a 2:1 ratio, respectively, for the six-month double-blind part. NeuroSense previously reported positive top-line results from the trial, including statistically significant slowing of disease progression and favorable safety and tolerability. The newly reported survival findings represent additional meaningful data generated from the same completed study, further enhancing the overall data package supporting PrimeC.

NeuroSense continues to engage with regulatory authorities regarding the advancement of PrimeC into pivotal late-stage development and believes these findings add important long-term clinical context to previously reported efficacy results.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding future development of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

For further information: For further information: Email: info@neurosense-tx.com | Tel: +972 (0)9 799 6183

Release – Kratos Awarded Contract to Streamline Hypersonic Material’s Development

Posted on February 18, 2026February 18, 2026 by aweinsoff@channelchek.com

Research News and Market Data on KTOS

February 18, 2026

PDF Version

In-Depth Modeling, Simulation of Hypersonic Environments Will Lead to a Robust Set of Hypersonic Test Setpoints to Enable Rapid Evaluation, Transition of Various Thermal Protection System Materials

SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in Defense, National Security and Global Markets, announced today that it has been awarded a contract through the Department of War’s Joint Hypersonics Transition Office to support test and evaluation of thermal protection systems for hypersonic vehicles. For this program, Kratos will leverage decades of expertise in hypersonics to analyze various missions and flight environments to understand appropriate testing conditions. Kratos will establish standard test conditions and techniques to accelerate materials development and can be used as a baseline for other similar aerothermal test facilities.

“The Kratos team is committed to advancing materials for hypersonics through testing and evaluation,” said Ben Dempsey, Kratos SRE Vice President of Programs. “Our focus is on accelerating the development of systems for our warfighter. This begins with increased throughput of our nation’s testing infrastructure, and by making investments in new infrastructure, like the recently awarded Project Helios.”

The test methodologies developed under this program will serve as a model for the hypersonic testing community, accelerating the advancement and deployment of next-generation U.S. hypersonic vehicle technologies. Additionally, Kratos will execute a series of material test campaigns leveraging these procedures that will validate the methodology and mature material solutions.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2024, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

Source: Kratos Defense & Security Solutions, Inc.

Release – V2X Awarded ATSP5 Contract to Advance Emerging Technology for the Warfighter

Posted on February 18, 2026February 18, 2026 by aweinsoff@channelchek.com

Research News and Market Data on VVX

February 18, 2026

Download(opens in new window)

RESTON, Va., Feb. 18, 2026 /PRNewswire/ — V2X Inc. (NYSE: VVX) proudly announces its selection for a seat on the Advanced Technology Support Program 5 (ATSP5), a $25 billion multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract. ATSP5, administered by the Defense Microelectronics Activity (DMEA) under the Office of the Secretary of Defense, is one of the Department of Defense’s most comprehensive engineering development and technology transition initiatives.

This contracting vehicle provides federal and state government agencies with streamlined access to V2X’s capabilities in delivering mission-critical solutions. The scope of ATSP5 includes engineering development, from system studies and prototyping to testing, integration, and limited production. It also includes full lifecycle technology support for embedded systems, network-centric warfare systems, large-scale integrations, and standalone systems. The program creates opportunities for modernization, overcoming obsolescence challenges, and extending the lifecycle of aging equipment while advancing cutting-edge technology such as AI-optimized systems and large-scale AI orchestration to address emerging threats.

As an ATSP5 program partner, V2X brings decades of expertise to solving complex engineering challenges through scalable, transformative solutions tailored to defense priorities. Its capabilities address key areas such as rapid acquisition, systems engineering, microelectronics supply assurance, digital prototyping, optimized automated testing, intelligent integration, performance optimization, and the intelligent application of advanced technologies with the aid of AI.

“Winning a position on the ATSP5 enables V2X as a leader in transformative engineering solutions,” said Jeremy C. Wensinger, President and Chief Executive Officer of V2X. “Our selection places us at the forefront of defense modernization, allowing us to deliver advanced capabilities that don’t simply respond to threats and system obsolescence, but anticipate and evolve with them. From AI-powered performance enhancement and autonomous system integration, we are redefining what operational resilience looks like in multi-domain operations. We are honored to contribute to the future of our nation’s warfighter operational superiority.”

In line with the Department of Defense’s most strategic modernization initiatives, V2X’s participation in ATSP5 underscores a commitment to advancing technology-first solutions for critical challenges faced by the warfighter. By deploying intelligent agents for modernizing government systems, advancing innovations, and addressing both traditional and asymmetric challenges, V2X will help ensure readiness and progress in support of the warfighter, while delivering solutions that reflect the highest standards of technical performance, security, and sustainability. V2X ensures unmatched readiness and technological overmatch in defense capabilities

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Media Contact
Angelica Spanos Deoudes
Director, Corporate Communications
Angelica.Deoudes@goV2X.com
571-338-5195

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-awarded-atsp5-contract-to-advance-emerging-technology-for-the-warfighter-302691291.html

SOURCE V2X, Inc.

Release – Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

Posted on February 18, 2026February 18, 2026 by aweinsoff@channelchek.com

Research News and Market Data on OCGN

February 18, 2026

PDF Version

MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026.

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 3029428
Webcast: Available on the events section of the Ocugen investor site

A replay of the call and archived webcast will be available on the Ocugen investor site.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com

Seanergy Maritime (SHIP) – Strong 2025 Finish; Favorable 2026 Outlook

Posted on February 18, 2026February 18, 2026 by slightbourne@noblecapitalmarkets.com

Wednesday, February 18, 2026

Seanergy Maritime Holdings Corp. is a prominent pure-play Capesize shipping company listed in the U.S. capital markets. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. The Company’s operating fleet consists of 18 vessels (1 Newcastlemax and 17 Capesize) with an average age of approximately 13.4 years and an aggregate cargo carrying capacity of approximately 3,236,212 dwt. Upon completion of the delivery of the previously announced Capesize vessel acquisition, the Company’s operating fleet will consist of 19 vessels (1 Newcastlemax and 18 Capesize) with an aggregate cargo carrying capacity of approximately 3,417,608 dwt. The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q4’25 financial results. Seanergy reported Q4 net revenues of $49.4 million and adjusted EBITDA of $28.9 million, exceeding our estimates of $48.3 million and $28.2 million, respectively. Adjusted net income and adjusted EPS were $14.2 million and $0.68, ahead of our $11.7 million and $0.56 estimates. The stronger than expected earnings were due to a higher average time charter equivalent (TCE) rate of $26,614 per day versus our $26,000 estimate.

Favorable Capesize market. The Capesize market is supported by favorable supply and demand fundamentals. The global orderbook stands at roughly 12% of the fleet, while approximately 40% of Capesize, Newcastlemax, and VLOC vessels are over 15 years old, with special surveys expected to reduce effective supply by 1.5% to 2.5% annually. Additionally, Brazilian iron ore exports and West African bauxite shipments continue to expand, with Simandou expected to add incremental long-haul volumes in 2026 and 2027. In our view, this combination of structural supply constraints and steady commodity trade flows supports a constructive rate environment throughout 2026.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

The AI Coding Boom Just Created a $1.5B Cloud Contender

Posted on February 18, 2026February 18, 2026 by slightbourne@noblecapitalmarkets.com

Cloud infrastructure startup Render has secured $100 million in new funding at a $1.5 billion valuation, underscoring how the artificial intelligence boom is reshaping the competitive landscape of cloud computing. As developers increasingly rely on AI tools to generate code and launch applications, platforms that simplify deployment and infrastructure management are seeing surging demand.

Founded in 2018 and headquartered in San Francisco, Render offers developers an easy way to deploy web apps, databases and background services without the operational complexity traditionally associated with major cloud providers. The company now counts more than 4.5 million developers on its platform and is growing revenue at well over 100% annually, according to CEO and co-founder Anurag Goel.

The broader cloud market has long been dominated by giants like Amazon, Microsoft and Alphabet. But the rise of generative AI, sparked by the 2022 debut of OpenAI’s ChatGPT, has shifted how software is built and deployed. Developers are now asking AI systems to write applications for them, dramatically lowering the barrier to creating new products. That shift is driving demand for infrastructure platforms that can instantly host and scale those AI-built applications.

Render operates on top of established cloud services such as Amazon Web Services and Google Cloud Platform, but it has also begun testing its own server infrastructure. Moving some workloads in-house could reduce long-term costs and give the company greater control over performance and pricing. However, owning hardware introduces new operational risks, including the need to carefully manage capacity to avoid shortages or downtime.

Investors backing Render include 01A, Addition, Bessemer Venture Partners, General Catalyst and Georgian Partners. The new capital will primarily fund hiring, particularly engineers focused on expanding platform capabilities and reliability.

Render’s growth also reflects changes among legacy platform providers. Salesforce recently indicated it would scale back new feature development for Heroku, once a pioneer in the platform-as-a-service category. That decision has left many developers searching for modern alternatives, and Render is positioning itself as a natural successor.

The company has attracted customers ranging from startups to established brands. AI-powered app builder Base44 uses Render for deployment, and its founder has invested in the company after experiencing the product firsthand. Other customers include e-commerce platforms, media companies and emerging AI startups seeking simplified infrastructure.

Notably, OpenAI’s Codex coding application allows users to deploy apps directly to Render, alongside options such as Cloudflare, Netlify and Vercel. As AI-generated software becomes more common, being integrated into these development workflows provides a powerful distribution channel.

Render’s rise highlights a broader trend: as AI makes software creation easier, infrastructure simplicity becomes a competitive advantage. In a market historically defined by scale and complexity, the winners of the AI era may be those that remove friction rather than add features.

Release – Superior Group of Companies to Announce Fourth Quarter and Full Year 2025 Results

Posted on February 17, 2026February 17, 2026 by aweinsoff@channelchek.com

Research News and Market Data on SGC

ST. PETERSBURG, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”) today announced that it will release the results of its operations for the fourth quarter and full year 2025 after the market close on Tuesday, March 3, 2026. Michael Benstock, Chairman and Chief Executive Officer, and Mike Koempel, President and Chief Financial Officer, will host a teleconference at 5:00 pm Eastern Time that day to discuss the Company’s results.

The live webcast and archived replay can be accessed in the investor relations section of the Company’s website at https://ir.superiorgroupofcompanies.com/presentations. Interested individuals may also join the teleconference by dialing 1-844-861-5505 for U.S. dialers and 1-412-317-6586 for international dialers. The Canadian toll-free number is 1-866-605-3852. Please ask to join to the Superior Group of Companies call.

A telephone replay of the teleconference will be available through March 17, 2026. To access the replay, dial 1-855-669-9658 in the United States and Canada or 1-412-317-0088 from international locations. Please reference conference number 6514610 for replay access.

About Superior Group of Companies, Inc. (SGC):
Established in 1920, Superior Group of Companies is comprised of three attractive business segments each serving large, fragmented and growing addressable markets. Across Healthcare Apparel, Branded Products and Contact Centers, each segment enables businesses to create extraordinary brand engagement experiences for their customers and employees. SGC’s commitment to service, quality, advanced technology, and omnichannel commerce provides unparalleled competitive advantages. We are committed to enhancing shareholder value by continuing to pursue a combination of organic growth and strategic acquisitions. For more information, visit www.superiorgroupofcompanies.com.

Contact:
Investor Relations
Investors@superiorgroupofcompanies.com

Release – Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica

Posted on February 17, 2026February 17, 2026 by aweinsoff@channelchek.com

Research News and Market Data on NTRB

ORLANDO, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary. Innomedica will also be overseeing and financing all regulatory approvals for the above mentioned products as they ramp up for launch.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband’s AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘’believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Release – GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far from Over

Posted on February 17, 2026February 17, 2026 by aweinsoff@channelchek.com

Research News and Market Data on GOVX

Company Highlights GEO-MVA Manufacturing Readiness and Clear Clinical Pathway to Support Global Supply Diversification

ATLANTA, GA – February 17, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today issued a statement endorsing the urgent call to action articulated by Rosamund Lewis, MD (WHO Head, Poxviruses Programme) and colleagues in their recently published PLOS Medicine article, “The mpox epidemic is not over: Reducing disproportionate burden in Africa and persistent global risk require a sustained response.” (https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004893&type=printable)

The article underscores that, despite declining attention in some regions, mpox transmission, morbidity, and mortality continue, particularly across Africa, driven by evolving viral clades, constrained vaccine supply, and persistent inequities in access to countermeasures. Dr. Lewis reinforced these concerns in a recent public call to action, emphasizing that sustained political will, financing, and expanded vaccine availability remain essential to controlling mpox as a global health threat.

“GeoVax strongly endorses Dr. Lewis’s message that the mpox epidemic is not over and that complacency would be a costly mistake,” said David Dodd, Chairman and Chief Executive Officer of GeoVax. “The data are clear: mpox continues to circulate, evolve, and disproportionately impact vulnerable populations. A durable response requires sustained investment, diversified vaccine supply, and readiness that extends beyond reactive surge manufacturing.”

GEO-MVA: Advancing Toward an Expanded Global MVA Vaccine Supply

GeoVax’s GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine for the prevention of mpox and smallpox, is being developed specifically to help address the structural vulnerabilities highlighted in the PLOS Medicine analysis – most notably the world’s continued dependence on a single manufacturer for licensed MVA vaccine supply.

Key GEO-MVA program milestones include:

Completion of GEO-MVA clinical material, positioning the program for late-stage clinical execution and supply readiness
Planned initiation of a pivotal Phase 3 immunobridging study in Q4 2026, aligned with formal Scientific Advice from the European Medicines Agency supporting an expedited registration pathway
Anticipated availability of immunobridging results in Q2 2027, supporting potential regulatory submissions and procurement discussions

“With a clearly defined regulatory pathway ahead, GEO-MVA is transitioning from preparedness planning to execution,” Dodd added. “This program is designed not only to meet regulatory requirements, but to support long-term global readiness by expanding MVA vaccine capacity in a market that remains chronically supply-constrained.”

Sustained Preparedness Requires Sustained Supply

The PLOS Medicine authors emphasize that mpox will continue to pose a global risk due to ongoing zoonotic spillover, viral evolution, and efficient transmission networks, particularly in settings where health systems are under-resourced. GeoVax believes these realities reinforce the need for redundant, geographically diversified MVA manufacturing capacity – a principle that underpins the GEO-MVA program.

“As the mpox response evolves from emergency reaction to long-term control, vaccine supply resilience becomes a cornerstone of preparedness,” said Dodd. “GeoVax is committed to supporting that objective by advancing GEO-MVA as an additional MVA vaccine option for public-health and biodefense stakeholders worldwide.”

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin^®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

info@geovax.com

678-384-7220

Media Contact:

Jessica Starman

media@geovax.com